The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON21342

Enrollment

500

Registered

2005-03-02

Start date

2002-12-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug: Amisulpride 200-800 mg/day Drug: Haloperidol 1-4 mg/day Drug: Olanzapine 5-20 mg/day Drug: Quetiapine 200-750 mg/day Drug: Ziprasidone 40-160 mg/day

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of schizophrenia; 2. Schizophreniform or schizoaffective disorder; 3. Age 18-40 years.

Exclusion criteria

Exclusion criteria: 1. A time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years; 2. Prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime; 3. Intolerance to one of the drugs in this study; 4. The presence of one or more of the contraindications against any of the study drugs.

Design outcomes

Primary

Measure	Time frame
Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. This outcome is assessed at regular time intervals until 12 months after recruitment.	—

Secondary

Measure	Time frame
At regular time intervals patients are followed-up until 12 months after recruitment: psychopathology (positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation), side effects (EPS side-effect profile, sexual side effects and weight gain), compliance, social needs, quality of life, substance abuse, neurocognitive functioning, and genetic determinants of response to antipsychotic drugs and natural history of schizophrenia.	—

Measure

Time frame

At regular time intervals patients are followed-up until 12 months after recruitment: psychopathology (positive symptoms, negative symptoms, depression, agitation-excitement, disorganisation), side effects (EPS side-effect profile, sexual side effects and weight gain), compliance, social needs, quality of life, substance abuse, neurocognitive functioning, and genetic determinants of response to antipsychotic drugs and natural history of schizophrenia.

—

Contacts

Public ContactHan Boter

University Medical Center Utrecht (UMCU), Department of Psychiatry, P.O. Box 85500

h.boter@azu.nl+31 (0)30 2509046

Outcome results